TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23619321

Group type: EXPERIMENTAL
Intervention: Single-incision laparoscopic cholecystectomy (SILC)
Number of subjects: 200

Group type: COMPARATOR
Intervention: Multiport laparoscopic cholecystectomy (4PLC)
Number of subjects: 200
Study: 21801750

Group type: EXPERIMENTAL
Intervention: Machine learning methods using Support Vector Machines (SVMs) for eye movement analysis during the Visual Paired Comparison (VPC) task.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Novelty preference information (traditional method).
Number of subjects: 0
Study: 19479072

Group type: EXPERIMENTAL
Intervention: Intensive lifestyle intervention (including physical activity, weight reduction, and dietary counseling)
Number of subjects: 522

Group type: COMPARATOR
Intervention: Control group (mini-intervention)
Number of subjects: 522
Study: 17704988

Group type: EXPERIMENTAL
Intervention: WS 5570 600 mg/day
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: WS 5570 1200 mg/day
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 14676561

Group type: COMPARATOR
Intervention: Propofol anesthesia (group 2)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Combined propofol-clonidine anesthesia (group 3)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Propofol and clonidine (group 3)
Number of subjects: 3
Study: 11423999

Group type: EXPERIMENTAL
Intervention: G-CSF (5 microg/kg/d) after PBPC transplantation at day 1
Number of subjects: 123

Group type: COMPARATOR
Intervention: No G-CSF administration
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Infusion of > 5 x 10(6)/kg CD34+ cells
Number of subjects: 123

Group type: COMPARATOR
Intervention: Infusion of ≤ 5 x 10(6)/kg CD34+ cells
Number of subjects: 123

Group type: COMPARATOR
Intervention: Patients with BM involvement
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Patients without BM involvement
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: G-CSF administration
Number of subjects: 123
Study: 9668370

Group type: EXPERIMENTAL
Intervention: GM‐1 ganglioside
Number of subjects: 797

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 797
Study: 8873964

Group type: EXPERIMENTAL
Intervention: Supervised, non-strenuous, weight-lifting exercise program (performed once a week at the medical facility and twice a week on their own)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Free physical activity (control group)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Loading and nonstrenuous strengthening exercises
Number of subjects: 96
Study: 2675700

Group type: EXPERIMENTAL
Intervention: Inhaled atropine sulfate
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study: 769527

Group type: EXPERIMENTAL
Intervention: Spironolactone (200 mg/day for 2 months)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Propranolol (320 mg/day for 2 months)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Combined administration of spironolactone and propranolol at half dosage
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 30888705

Group type: EXPERIMENTAL
Intervention: Inhibitory control training
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Working memory training
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control training condition
Number of subjects: 0
Study: 28258263

Group type: EXPERIMENTAL
Intervention: Upbeat music distraction group
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Relaxing music distraction group
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 26096296

Group type: EXPERIMENTAL
Intervention: Docetaxel/capecitabine (TX)
Number of subjects: 206

Group type: COMPARATOR
Intervention: Vinorelbine/capecitabine (NX)
Number of subjects: 206
Study: 22925088

Group type: EXPERIMENTAL
Intervention: Osteotome sinus floor elevation (OSFE) without grafting material (test group)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Osteotome sinus floor elevation (OSFE) with grafting material (control group)
Number of subjects: 12
Study: 21672217

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT)
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Interpersonal therapy (IPT)
Number of subjects: 180

Group type: COMPARATOR
Intervention: Waiting list condition
Number of subjects: 180
Study: 19348819

Group type: EXPERIMENTAL
Intervention: Blankets warmed to 110 degrees F (43 degrees C)
Number of subjects: 3

Group type: EXPERIMENTAL
Intervention: Blankets warmed to 150 degrees F (66 degrees C)
Number of subjects: 3

Group type: COMPARATOR
Intervention: Unheated blankets
Number of subjects: 3
Study: 16813590

Group type: EXPERIMENTAL
Intervention: Laparoscopic rectal cancer surgery
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open rectal cancer surgery
Number of subjects: 0
Study: 14752411

Group type: EXPERIMENTAL
Intervention: 20 ppm of inhaled nitric oxide
Number of subjects: 29

Group type: COMPARATOR
Intervention: No additional inhalatory treatment
Number of subjects: 29
Study: 11045858

Group type: EXPERIMENTAL
Intervention: Pregnancy
Number of subjects: 3962

Group type: EXPERIMENTAL
Intervention: Oral contraceptives
Number of subjects: 3962

Group type: EXPERIMENTAL
Intervention: Postmenopausal status
Number of subjects: 3962

Group type: COMPARATOR
Intervention: Fertile stage
Number of subjects: 3962

Group type: EXPERIMENTAL
Intervention: gamma-CDT
Number of subjects: 3962
Study: 9206771

Group type: EXPERIMENTAL
Intervention: Nomegestrol acetate 5 mg daily per os
Number of subjects: 56

Group type: COMPARATOR
Intervention: Didrogesteron 10 mg twice a day per os
Number of subjects: 56
Study: 8320052

Group type: EXPERIMENTAL
Intervention: Multivitamin supplement taken daily for 4 months
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo taken daily for 4 months
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multivitamin supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3558026

Group type: EXPERIMENTAL
Intervention: Extended field irradiation followed by a boost to the prostate
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Hormonal management prior to or during radiotherapy
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Age
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Tumor size
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Serum acid phosphatase elevation
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Nodal status
Number of subjects: 566

Group type: EXPERIMENTAL
Intervention: Concomitant hormonal management
Number of subjects: 566
Study: 31022105

Group type: EXPERIMENTAL
Intervention: SQ + LST
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: SQ + HST
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: LST
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: HST
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: SQ
Number of subjects: 91
Study: 29926912

Group type: EXPERIMENTAL
Intervention: Levosimendan (0.1 and 0.2 μg/kg/min)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Milrinone (0.4 and 0.8 μg/kg/min)
Number of subjects: 31
Study: 27305903

Group type: EXPERIMENTAL
Intervention: Religiously integrated cognitive behavioral therapy (RCBT)
Number of subjects: 132

Group type: COMPARATOR
Intervention: Conventional cognitive behavioral therapy (CCBT)
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Higher baseline DSE
Number of subjects: 132

Group type: EXPERIMENTAL
Intervention: Increase in DSE with treatment
Number of subjects: 132
Study: 25715558

Group type: EXPERIMENTAL
Intervention: Bicanalicular Mini‐Monoka and Monoka stents
Number of subjects: 151

Group type: COMPARATOR
Intervention: Bicanalicular SRS and Ritleng stents
Number of subjects: 151
Study: 22271284

Group type: EXPERIMENTAL
Intervention: Telerehabilitation SLP (T‐SLP)
Number of subjects: 40
Study: 20665514

Group type: EXPERIMENTAL
Intervention: IGIV-C (Gamunex) administered every 3 weeks for up to 24 weeks
Number of subjects: 117

Group type: COMPARATOR
Intervention: Placebo administered every 3 weeks for up to 24 weeks
Number of subjects: 117
Study: 18520504

Group type: EXPERIMENTAL
Intervention: Tissue glue (Tisseel)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Vicryl sutures
Number of subjects: 24
Study: 15777301

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% alone
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% plus 10 microg sufentanil
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Ropivacaine 1% plus 20 microg sufentanil
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (Ropivacaine 1% alone)
Number of subjects: 60
Study: 12481972

Group type: EXPERIMENTAL
Intervention: Enhanced Behavioral Family Intervention (EBFI)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Standard Behavioral Family Intervention (SBFI)
Number of subjects: 87

Group type: COMPARATOR
Intervention: Waitlist Control (WL)
Number of subjects: 87

Group type: EXPERIMENTAL
Intervention: Both BFI programs (EBFI and SBFI)
Number of subjects: 87
Study: 10726441

Group type: EXPERIMENTAL
Intervention: Transdermal hormonal therapy with 50 micrograms of ethynilestradiol and 5 mg of MAP
Number of subjects: 30

Group type: COMPARATOR
Intervention: Tibolone 2.5 mg
Number of subjects: 30
Study: 7718318

Group type: EXPERIMENTAL
Intervention: Melphalan 15 mg/m2 intravenously (i.v.) and prednisone 60 mg/m2 oral days 1‐4 (MP)
Number of subjects: 406

Group type: COMPARATOR
Intervention: VBAMDex (vincristine/BCNU/doxorubicin/melphalan/dexamethasone)
Number of subjects: 406

Group type: EXPERIMENTAL
Intervention: IFN‐alpha (5 x 10(6) IU, subcutaneous (S.C.) 3 times per week)
Number of subjects: 406

Group type: COMPARATOR
Intervention: No maintenance treatment
Number of subjects: 406
Study: 1818628

Group type: EXPERIMENTAL
Intervention: Therapeutic concept including effective motivation; specific details on dosage and duration not available.
Number of subjects: 0
Study: 7445641

Group type: EXPERIMENTAL
Intervention: Urografin 76% (ionic contrast medium)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Urografin 76% with added calcium (22.5 mEq/l)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Urografin 76% with added calcium (33.75 mEq/l)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Urografin 76%
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Urografin 76% with added calcium (higher volumes)
Number of subjects: 16
Study: 30997482

Group type: EXPERIMENTAL
Intervention: Multidomain intervention targeting weight loss
Number of subjects: 319

Group type: COMPARATOR
Intervention: Control condition of diabetes support and education
Number of subjects: 319
Study: 31061515

Group type: EXPERIMENTAL
Intervention: Mindfulness training (MT) for 8 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Active control training (CT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: One-time mindfulness induction (MI)
Number of subjects: 0
Study: 28634320

Group type: EXPERIMENTAL
Intervention: Continuous intraarticular block (CIAB)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Continuous femoral nerve block (CFNB)
Number of subjects: 54
Study: 25887469

Group type: EXPERIMENTAL
Intervention: Epidural injection of glucocorticoids
Number of subjects: 116
Study: 24299218

Group type: EXPERIMENTAL
Intervention: Trifecta valve (St. Jude Medical)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Mitroflow valve (Sorin Group)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Carpentier‐Edwards Magna Ease valve (Edwards Lifesciences)
Number of subjects: 0
Study: 21425506

Group type: EXPERIMENTAL
Intervention: neosaxitoxin (neoSTX)
Number of subjects: 137

Group type: COMPARATOR
Intervention: bupivacaine
Number of subjects: 137
Study: 19715043

Group type: EXPERIMENTAL
Intervention: Weight control expectancies through smoking
Number of subjects: 117

Group type: EXPERIMENTAL
Intervention: Concerns about weight gain upon cessation
Number of subjects: 117
Study: 17729399

Group type: EXPERIMENTAL
Intervention: Kiwifruit (twice daily for 4 weeks)
Number of subjects: 33
Study: 15056829

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg/day
Number of subjects: 63

Group type: COMPARATOR
Intervention: Quinapril 10 mg/day
Number of subjects: 63
Study: 12233807

Group type: EXPERIMENTAL
Intervention: Leech therapy (4 leeches applied topically at painful periarticular sites)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional treatment for pain (excluding nonsteroidal anti-inflammatory drugs)
Number of subjects: 16
Study: 9848971

Group type: EXPERIMENTAL
Intervention: Personal approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Letter
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study: 8010369

Group type: EXPERIMENTAL
Intervention: Alternating time schedule of bright light treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fixed morning schedule of bright light treatment
Number of subjects: 31

Group type: COMPARATOR
Intervention: Fixed evening schedule of bright light treatment
Number of subjects: 31
Study: 2671449

Group type: EXPERIMENTAL
Intervention: Nisoldipine (2.5 mg once a day, increased to 5-10 mg per day for 12 weeks)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Nifedipine or Atenolol (control)
Number of subjects: 149
Study: 1098807

Group type: EXPERIMENTAL
Intervention: Unclamped group
Number of subjects: 41

Group type: COMPARATOR
Intervention: Clamped group
Number of subjects: 41
Study: 31021265

Group type: EXPERIMENTAL
Intervention: Normoxic whole-body vibration (NWBV) group (n=11)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Hypoxic whole-body vibration (HWBV) group (n=10)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (n=10)
Number of subjects: 31
Study: 28403644

Group type: EXPERIMENTAL
Intervention: Insulin glargine
Number of subjects: 129

Group type: COMPARATOR
Intervention: Standard care
Number of subjects: 129
Study: 25415245

Group type: EXPERIMENTAL
Intervention: Antimicrobial photodynamic therapy (aPDT) + Scaling and Root Planing (SRP)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Scaling and Root Planing (SRP) only
Number of subjects: 20
Study: 23233423

Group type: EXPERIMENTAL
Intervention: Automated framework for identifying medication overuse
Number of subjects: 200

Group type: COMPARATOR
Intervention: Manual review by two gastroenterologists
Number of subjects: 200
Study: 21241987

Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide (HCTZ)
Number of subjects: 207

Group type: COMPARATOR
Intervention: Azelnidipine
Number of subjects: 207
Study: 18280939

Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine gluconate (Chx)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.12% chlorhexidine gluconate with 0.15% benzydamine hydrochloride (Chx+Bzd)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 7.5% polyvinylpyrrolidone iodine (Pvp)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 0.15% benzydamine hydrochloride (Bzd)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Sterile saline solution (Ss)
Number of subjects: 80
Study: 15854874

Group type: EXPERIMENTAL
Intervention: Questionnaire measure of the relative reinforcing value of snack food versus fruits and vegetables (condition 1)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Questionnaire measure of the relative reinforcing value of snack food (Study 2)
Number of subjects: 49
Study: 12543740

Group type: EXPERIMENTAL
Intervention: Educational video (4.5 minute audiovisual presentation)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Control group (no video)
Number of subjects: 244
Study: 10805050

Group type: EXPERIMENTAL
Intervention: Hypertension prevalence
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Hypertension prevalence in men
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Hypertension prevalence in women
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Association with higher salary grade
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Obesity and hypertension in women
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Significant variables for systolic blood pressure
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Significant variables for diastolic blood pressure
Number of subjects: 998

Group type: EXPERIMENTAL
Intervention: Predictors of hypertension
Number of subjects: 998
Study: 9132505

Group type: EXPERIMENTAL
Intervention: Caffeine (125 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cornstarch (control)
Number of subjects: 0
Study: 1535229

Group type: EXPERIMENTAL
Intervention: 5 micrograms hepatitis B vaccine
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 2 micrograms hepatitis B vaccine
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: 1 microgram hepatitis B vaccine
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Low anti-HBs titres (10-100 miu/mL)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Medium anti-HBs titres (101-1000 miu/mL)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: High anti-HBs levels (greater than 1000 miu/mL)
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Natural booster response
Number of subjects: 267
Study: 6707051

Group type: EXPERIMENTAL
Intervention: 0.5 g gentamicin base per 40 g pack of powdered polymer
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1.0 g gentamicin base per 40 g pack of powdered polymer
Number of subjects: 30
Study: 29952235

Group type: EXPERIMENTAL
Intervention: Jaw Dynasplint
Number of subjects: 40

Group type: COMPARATOR
Intervention: Conventional stretching
Number of subjects: 40
Study: 27454492

Group type: EXPERIMENTAL
Intervention: Nutrition education intervention using developed CD-ROMs and interactive sessions
Number of subjects: 40
Study: 24001275

Group type: EXPERIMENTAL
Intervention: Sedentary (uninterrupted sitting)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Breaks (sitting interrupted with a 2 min light-intensity walk break every 20 min)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Breaks+PA (sitting interrupted with a 2 min light-intensity walk break every 20 min and 2 × 20 min of moderate-intensity PA)
Number of subjects: 20
Study: 22675960

Group type: EXPERIMENTAL
Intervention: alfentanil 10 microg/kg IV with propofol 0.7 mg/kg IV
Number of subjects: 60

Group type: COMPARATOR
Intervention: ketamine 0.5 mg/kg IV with propofol 0.7 mg/kg IV
Number of subjects: 60
Study: 20367516

Group type: EXPERIMENTAL
Intervention: Aquatic therapy (6 sessions, once weekly for 30 min over 6-8 weeks)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Wait-list (control group)
Number of subjects: 13
Study: 18586313

Group type: EXPERIMENTAL
Intervention: CA-125 level measurement using Centocor CA-125II RIA assay
Number of subjects: 25608

Group type: EXPERIMENTAL
Intervention: CA-125 level measurement
Number of subjects: 25608

Group type: EXPERIMENTAL
Intervention: Current hormone therapy use
Number of subjects: 25608
Study: 15791969

Group type: COMPARATOR
Intervention: Conventional tension‐free meshplasty
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Repair through a single 2‐cm to 2.5‐cm skin incision with laparoscopic assistance
Number of subjects: 50
Study: 12482559

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg
Number of subjects: 186

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 186
Study: 10680388

Group type: EXPERIMENTAL
Intervention: Posture training and TMD self-management instructions
Number of subjects: 60

Group type: COMPARATOR
Intervention: TMD self-management instructions only
Number of subjects: 60
Study: 9493481

Group type: EXPERIMENTAL
Intervention: Divalproex
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8446743

Group type: EXPERIMENTAL
Intervention: E (epinephrine) 82 pmol/kg/min
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: NE (norepinephrine) 178 pmol/kg/min
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (saline, 5.4 ml/hr)
Number of subjects: 10
Study: 3011834

Group type: EXPERIMENTAL
Intervention: T4 treatment group (L-T4 1.5 micrograms/kg iv daily for 2 weeks)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Control group (no T4 treatment)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Both groups (survivors and nonsurvivors)
Number of subjects: 23
Study: 29691923

Group type: EXPERIMENTAL
Intervention: 2% homatropine with hyperopic defocus (‐3.00 D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo with hyperopic defocus (‐3.00 D)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo with myopic defocus (+3.00 D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2% homatropine with myopic defocus (+3.00 D)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Homatropine alone
Number of subjects: 30
Study: 27641143

Group type: EXPERIMENTAL
Intervention: Romosozumab (210 mg subcutaneous injections monthly for 12 months)
Number of subjects: 7180

Group type: COMPARATOR
Intervention: Placebo (subcutaneous injections monthly for 12 months)
Number of subjects: 7180

Group type: EXPERIMENTAL
Intervention: Romosozumab (after transition to denosumab)
Number of subjects: 7180

Group type: COMPARATOR
Intervention: Placebo (after transition to denosumab)
Number of subjects: 7180
Study: 24828268

Group type: EXPERIMENTAL
Intervention: Active PrEP
Number of subjects: 4747

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 4747
Study: 22517351

Group type: EXPERIMENTAL
Intervention: Guided imagery presentation via the Internet
Number of subjects: 29
Study: 20492573

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (800 microg) administered as a single film
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fentanyl buccal soluble film (200 microg) administered as four separate films simultaneously
Number of subjects: 12

Group type: COMPARATOR
Intervention: Injectable fentanyl citrate (200 microg) administered by intravenous infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Injectable fentanyl citrate (800 microg/16 mL) administered orally
Number of subjects: 12
Study: 17694505

Group type: EXPERIMENTAL
Intervention: Pramlintide (120 microg)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study: 15912479

Group type: EXPERIMENTAL
Intervention: 12-week group (NT screening)
Number of subjects: 39572

Group type: COMPARATOR
Intervention: 18-week group (maternal age-based screening)
Number of subjects: 39572
Study: 12860904

Group type: EXPERIMENTAL
Intervention: 6-month exercise training program (T, n=45)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (C, n=45)
Number of subjects: 90
Study: 10520076

Group type: EXPERIMENTAL
Intervention: Active grass pollen immunotherapy
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo injections
Number of subjects: 40